



# Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

## Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,  
Opp. PCI, Ankleshwar – 393 002,  
Gujarat, India  
Tel : (02646) 220774  
Fax : (02646) 251291  
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

## Corporate Office

701/702, Business Square,  
M. A. Road, Andheri (West),  
Mumbai – 400 058, India.  
Tel : (91-22) 26701050/1/2  
Fax : (91-22) 26701053  
E: contact@samratpharmachem.in

**July 29, 2020**

To,  
**Department of Corporate Services,  
BSE Limited**  
25th Floor, P J Towers,  
Dalal Street,  
Mumbai - 400 001.

Dear Sir,

### **Sub: Reconciliation of Share Capital Audit f.t.q.e. 30/06/2020**

Pursuance to Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018, we are forwarding herewith a Certificate issued by Practicing Company Secretary after conducting Reconciliation of Share Capital Audit for the quarter ended June 30, 2020.

Thanking you,

Yours faithfully,  
**For Samrat Pharmachem Limited**

**Nishant Kankaria**  
**Company Secretary & Compliance Officer**

**Aqueel A. Mulla**

B.Com., L.L.M., F.C.S., A.C.I.S. (U.K.), D.I.T., Ph.D

**A. A. MULLA & ASSOCIATES**  
**Company Secretaries**

---

Room No.603, A Wing, 6<sup>th</sup> Floor, Dhamm Seva CHS, Deluxe Building,  
Opp. Kurla Station East, Mumbai – 400 024.  
M: 9892237418 Email: aqueelmulla@gmail.com

**July 29, 2020**

**The Board of Directors,**  
**M/s. Samrat Pharmachem Limited**  
Plot No. A2/3445,  
GIDC, Phase 4,  
Ankleshwar – 393 002,  
Gujarat.

Dear Sir,

Pursuance to Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018, we are enclosing herewith a Certificate issued by us after conducting Reconciliation of Share Capital Audit for the quarter ended **30<sup>th</sup> June, 2020**, as required under the said circular.

Please find the same in order & forward a copy of the same to the respective stock exchanges.

Yours faithfully,  
**For A.A. Mulla & Associates**  
**Company Secretaries**



**Aqueel A. Mulla**  
**Proprietor**

**UDIN: F002973B000522910**

## Reconciliation of Share Capital Audit Report

(As per Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018).

Sr. No	Particulars	Details	
1.	For Quarter Ended	30 <sup>th</sup> June, 2020	
2.	ISIN	INE103E01016	
3.	Face Value	Rs. 10	
4.	Name of the Company	Samrat Pharmachem Limited	
5.	Registered Office Address	Plot No. A2/3445, GIDC, Phase 4, Ankleshwar – 393 002, Gujarat.	
6.	Correspondence Address	701/702, Business Square, M. A. Road, Andheri (West), Mumbai – 400 058.	
7.	Tel No. & Fax No.	Tel : (022) 26701050 Fax : (022) 26701053	
8.	Email Address Website	contact@samratpharmachem.in www.samratpharmachem.com	
9.	Names of the stock exchanges where the company's securities are listed.	Mumbai	
10.	Issued Capital	No. of shares	% of total issued capital
		30,89,700	100.00 %
11.	Listed Capital (Exchange Wise) As per company records ▪ It is same for all the exchanges	30,89,700	100.00 %
12.	Held in dematerialized form in CDSL	4,11,879	13.33 %
13.	Held in dematerialized form in NSDL	23,12,911	74.86 %
14.	Physical	3,64,910	11.81 %
15.	Total No. of shares (12+13+14)	30,89,700	100.00 %
16.	Reasons for difference if any, between (10&11), (10&15), (11&15)	Nil	

17. Certifying the details of changes in share capital during the quarter under consideration as per table below:

Particulars ***	No. of shares	Applied / Not applied for listing	Listed on stock exchanges (specify names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Appr. Pending for SE (Specify Names)
Nil	Nil	Nil	Nil	Nil	Nil	Nil

\*\*\* Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, any other (to specify)

18.	Registrar of members is updated (Yes/No)	Yes
	If not, updated upto which date	Not Applicable




19. Reference of previous quarter with regards to excess de-materialised shares, if any.


20. Has the Company resolved the matter mentioned in Point No. 19 above in the current quarter? If not, reason why?

21. Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay :

Total No. of demat requests	No. of requests	No. of shares	Reason for delay
Confirmed after 21 days	0	0	-
Pending for more than 21 days	0	0	-

22.	Name, Tel No., Fax No. & Membership No. of the Compliance Officer of the Co.	Name : Mr. Nishant Anandkumar Kankaria Tel No. : (91-22) 26701050 Fax No. : - Membership : ACS-59905 No. Email : contact@samratpharmachem.in
-----	--	---

23.	Name, Address, Tel No. & Fax No., Regn No. of the Certifying CA/CS	Name : A. A. Mulla & Associates Company Secretaries Address : Room No.603, A Wing, 6th Floor, Dhamm Seva CHS, Deluxe Building, Opp Kurla Station East, Mumbai-400024 Tel No. : (91) 9892237418 Email : aqueelmulla@gmail.com
-----	--	---

24.	Appointment of common agency for share registry work	Name : Link Intime India Pvt Ltd Address : C-101, 247 Park, L. B. S. Marg, Vikhroli (West), Mumbai – 400 083, Maharashtra. Tel No. : (022) 49186000 Fax No. : (022) 49186060 Email : rnt.helpdesk@linkintime.co.in Kind Attn : Ms. Shweta Poojari
-----	--	--

25. Any other detail that the CA/CS may like to provide (eg BIFR Company, de-listing from SE, etc)

**Date : July 29, 2020**  
**Place : Mumbai**

**For A. A. Mulla & Associates**  
**Company Secretaries**



**Aqueel A Mulla**  
**Proprietor**  
**C.P. No. 3237**  
**CS No. 2973**  
**UDIN: F002973B000522910**